We introduce a new model called the observed time conjunctive Bayesian network (OT-CBN) that describes the accumulation of genetic events (mutations) under partial temporal ordering constraints. Unlike other CBN models, the OT-CBN model uses sampling time points of genotypes in addition to genotypes themselves to estimate model parameters. We developed an expectation-maximization algorithm to obtain approximate maximum likelihood estimates by accounting for this additional information. In a simulation study, we show that the OT-CBN model outperforms the continuous time CBN (CT-CBN) (Beerenwinkel and Sullivant, 2009 . Markov models for accumulating mutations. Biometrika 96(3), 645-661), which does not take into account individual sampling times for parameter estimation. We also show superiority of the OT-CBN model on several datasets of HIV drug resistance mutations extracted from the Swiss HIV Cohort Study database.
INTRODUCTION
HIV drug resistance development is a consequence of viral evolution. This evolutionary process is characterized mainly by the accumulation of resistance mutations, i.e. mutations that confer a selective advantage
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715 at sampling time t s,i for the ith observation and N is the number of observations. Simulation studies and application to several HIV datasets from the SHCS show that using the sampling times significantly improves accuracy of parameter estimation and model selection.
This paper is organized as follows. In Section 2, we formally introduce the OT-CBN. In Section 2, we present the EM algorithm for approximating the ML estimates of the model. Section 3 reports performance measures of the OT-CBN and CT-CBN models in different simulation settings. In Section 4, the applications of the OT-CBN model to several datasets of HIV drug resistance mutations are presented. Finally, we close with conclusions in Section 5.
OBSERVED TIME CONJUCTIVE BAYESIAN NETWORKS
In this section, we introduce the OT-CBN and derive some of its properties. The OT-CBN model, like other CBN models, is a non-ergodic continuous time Markov chain model on the distributive lattice of a partially ordered set (poset) of events. In our model, the poset P is a set of genetic events (i.e. mutations) with ground set [n] = {1, . . . , n} and a transitive relation which specifies constraints on the order in which events can occur. We use the terms "event" and "mutation" interchangeably in this paper. The relation i ≺ j implies that event i must happen before event j. The state space of the OT-CBN model is J (P) × R + . Each observation consists of a genotype g ∈ J (P) and its sampling time t ∈ R + where J (P) is the distributive lattice of order ideals of P. An order ideal is a subset of events g ⊆ P for which i ∈ g whenever i ≺ j and j ∈ g. The order ideals in J (P) correspond to the genotypes (or mutational patterns, or subsets of mutations) compatible with the poset P. The wild type is denoted by ∅ ∈ J (P) and is defined as the genotype carrying no mutation. For each event i ∈ P, we define an exponentially distributed random variable Z i ∼ Exp(λ i ) and a random variable T i as
where pa(i) is the set of parents of event i in the poset P. The random variable T i represents the occurrence time of event i by assuming that no events have been observed at time zero. The random variable T i is not observed. The density function of the random vector
where n = (λ 1 , . . . , λ n ) ∈ R n + , and the density function f λ i is the univariate exponential probability density function. The density function f P, is zero if there exists an event i ∈ P such that t i < max j∈ pa(i) t j . A genotype with occurrence times t is said to be compatible with the poset P if f P, (t) > 0, or equivalently if t i max j∈pa(i) t j for all i ∈ P, i.e. if no mutation occurred before any of its predecessor mutations in the poset.
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(a) (b) Fig. 1 . The poset P, consisting of four elements subject to the relations 1 ≺ 3, 2 ≺ 3, and 2 ≺ 4, is shown in (a). Each vertex labeled i ∈ P represents the random variable T i that describes the waiting time for event i. The corresponding genotype lattice J (P), consisting of eight genotypes compatible with the poset P, is shown in (b).
and otherwise the density is zero. Figure 1 (a) and 1(b) of supplementary material available at Biostatistics online illustrate two realizations of the random variables T i and Z i for the chains 1 ≺ 2 ≺ 3 ≺ s ≺ 4 and 2 ≺ 1 ≺ s ≺ 4 ≺ 3, respectively, where s is the sampling event.
Let g ∈ J (P) be a genotype. The set Exit(g) = { j ∈ P | j / ∈ g, g ∪ j ∈ J (P)} is the set of events that are not in g but that can happen next. We define for any subset A ⊆ P, λ A = j∈A λ j , and T A = {T j | j ∈ A}. The complement of a genotype g is denoted byḡ = P \ g. We define the poset Q g by adding a new event s for the sampling time t s to the poset P, i.e. Q g = P ∪ s. The poset Q g has extra relations imposed by the observed genotype g. In addition to the relations in the poset P, it consists of the relations i ≺ s for all i ∈ g and s ≺ i for all i / ∈ g. The poset Q g is said to refine the poset P by the genotype g. Figure 2 (a) and (c) of supplementary material available at Biostatistics online show the refinements of the poset P, defined in Example 2.1, for the genotypes {1, 2} and {1, 2, 3}, respectively.
A chain in J (P) is a collection of subsets C 0 , . . . , C k ∈ J (P) with C i C i+1 for all i. A chain with maximum length is called a maximal chain. Maximal chains in J (P) have length n + 1 with n = |P|. We denote by C(J (P)) the set of all maximal chains in J (P). For any maximal chain, C = (C 0 , . . . , C n ), we have C 0 = ∅ and C n = P. For every maximal chain C in J (Q g ), in addition it holds that C |g| = g. Equivalently, a chain is denoted by the sequence of corresponding events, Figure 2 (b) and (d) of supplementary material available at Biostatistics online show the genotype lattices refined by the genotypes {1, 2} and {1, 2, 3} for the poset P of Example 2.1, respectively. For the genotype lattice J (P), there are five maximal chains 1 → 2 → 3 → 4, 1 → 2 → 4 → 3, 2 → 1 → 3 → 4, 2 → 1 → 4 → 3, and 2 → 4 → 1 → 3, while the refined genotype lattice J (Q {1,2,3} ) consists of only two maximal chains 1 → 2 → 3 → 4 and 2 → 1 → 3 → 4. The chain 2 → 1 → 3 → 4 is denoted alternatively by C = (∅, {2}, {2, 1}, {2, 1, 3}, {2, 1, 3, 4}).
Let T be a random vector of mutation occurrence times and g be an observed genotype at sampling time t s . The random variable T is said to be compatible with a poset P, denoted by T P, if T i T j for every i ≺ j in P. We use the notation (T, t s ) Q g when the random vector (T, t s ) is compatible with the refined poset Q g . THEOREM 2.3 Let the random vector T , as defined in (2.1), be compatible with the poset P, i.e. T P. Then the probability that T is compatible with the refined poset Q g at sampling time t s is
where l = |g| is the number of mutations in genotype g and
Proof. The proof is given in supplementary material available at Biostatistics online.
EXAMPLE 2.4 Let P be the poset defined on the ground set {1, 2, 3} with the relations 1 ≺ 2 and 1 ≺ 3 (Figure 2(a) ). The possible genotypes are ∅, {1}, {2}, {1, 2}, {1, 2, 3}. The corresponding genotype lattice of this poset, J (P), is displayed in Figure 2 (b). The probabilities of observing different genotypes are shown in Figure 2 (c). Theorem 2.3 is used to compute these probabilities. The wild type is the dominant genotype in the very beginning of the evolutionary process (small sampling times). For higher sampling times, the fully resistant genotype becomes dominant.
The estimation of the OT-CBN model consists of two parts: learning the ML poset and estimating the ML rate parameters for a given poset. We will discuss the poset learning in Section 4. In the rest of this section, we present a method to perform parameter estimation for a given poset using observed genotypes and sampling times. Since occurrence time for each mutation, t i , is a latent variable in the joint density function (2.2), it is not possible to compute the density (2.2) from observed data. Hence, we use the EM algorithm to find approximate ML estimates of the rate parameters λ.
In the E-step of the EM algorithm, for each mutation i ∈ P, we need to compute the expected value,
, for each pair of observed genotype and sampling time, (g, t s ). These expected values are the expected sufficient statistics for λ, therefore in the M-step of the EM algorithm, the new estimate of
where N is the number of observations. Theorem 2.5 can be used to compute this expectation. Similar to the technique used in Theorem 2.3, the integration required for computing the expectation is decomposed into sum of integrals over simpler regions. Each of these integrals is then computed by the recursive formula given in Proposition 2 of supplementary material available at Biostatistics online, Appendix C.
∈ C k and pa(i) ⊆ C k , and 0 otherwise, and the function ζ s is defined as
. . .
In summary, we developed a new EM algorithm for the estimation of the evolutionary rates for the given poset structure. In the E-step, the conditional expected values of random variable T i − max j∈pa(i) T j (or simply Z i ) is computed for each observation and each mutation i ∈ P. In the M-step, these expected values are then used to compute the MLEs for the rate parameters λ. The EM algorithm is implemented in the R language and the code is available at: http://www.cbg.ethz.ch/software/otcbn. Tables 1-3 of supplementary material available at Biostatistics online).
In our simulation experiments, we studied 6 different posets: two empty posets and two linear posets each with four and six events, the poset shown in Figure 1 (a) and the poset depicted in Figure 3 of supplementary material available at Biostatistics online. We investigated different sampling time distributions, namely sampling at constant time c for all samples (the density function is δ(c) where δ(·) is the Dirac delta function), exponential sampling time distribution T s ∼ exp(λ s ), normal sampling time distribution N (μ s , σ s ), and a distribution in which sampling time depends on the mutational process. The dependent sampling time distribution is a mixture of the distribution of max(T 1 , T 2 ) (the waiting time to the occurrence of both the first and second mutation) and a uniformly distributed component to introduce variability into the simulated datasets. The weight of the uniform component is 0.05. The parameters of the different sampling distributions except the dependent distribution are selected such that the expected value of the sampling time is equal to one. Hence, all the parameters c, λ s , and μ s are equal to one and the standard error of the normal distribution is set to σ s = μ s /10. For each poset, the rate parameter of each mutation, λ e , was generated by drawing uniform random numbers between 1 2 and 2 (between two-fold slower and faster than average sampling time).
We drew N pairs of genotypes and corresponding sampling times, (g i , t s,i ) for i = 1, . . . , N , for each parameter setting. The OT-CBN and CT-CBN models were estimated and compared using the simulated Tables 1-3 of supplementary material available at Biostatistics online. For constant, normal, and dependent sampling distributions, the OT-CBN outperforms the CT-CBN in 87 comparisons out of a total of ninety comparisons (83 of them are significant). The CT-CBN model assumes that sampling times are distributed exponentially and hence its performance is better for exponential sampling distribution. Even in this case, the OT-CBN still outperforms the CT-CBN in 24 comparisons (only one of them is significant) and the CT-CBN is better in the other six comparisons (only two of them are significant). Tables 4-6 of supplementary material available at Biostatistics online show the similar results when the relative mean squared error is used as the performance measure. No major difference has been observed between the results of two performance measures.
It is evident from the simulation results that the OT-CBN is more accurate than the CT-CBN model in the estimation of the rate parameters for different posets and sampling time distributions. The superiority of the OT-CBN model is due to the fact that firstly this model takes into account not only observed genotypes but also observed sampling times for parameter estimation, and secondly as opposed to the CT-CBN model, the OT-CBN model makes no assumptions on the distribution of the sampling time and its independence of the mutational process.
HIV GENETIC DATA
In this section, we analyze five datasets obtained from the SHCS database (Schoeni-Affolter and others, 2010) (Table 7 of supplementary material available at Biostatistics online). We want to model the accumulation of resistance mutations in the reverse transcriptase gene of the HIV viral genome under monotherapy with zidovudine (ZDV) or combination therapy with zidovudine plus lamivudine (ZDV+3TC) or any therapy consisting of ZDV (denoted by ZDV+ * ). Resistance mutations for each therapy are selected from Johnson and others (2013) and reported in Table 7 of supplementary material available at Biostatistics online. The mutation 67N, for instance, indicates amino acid asparagine (N) has been observed at position 67 of the reverse transcriptase gene of the HIV viral genome. The datasets ZDV-fl and ZDV+3TC-fl only contain genotypes for first-line (fl) therapies, while the other datasets consist of genotypes for both firstline and salvage therapies. For all datasets, the sampling time of each individual genotype is observed. By applying the one-sample Kolmogorov-Smirnov test, we found that sampling time distributions deviate significantly from the exponential distribution, for all datasets. Figure 5 of supplementary material available at Biostatistics online shows to what extent each dataset deviates from the exponential assumption. Hence, one of the assumptions of the CT-CBN model is violated and we expect the OT-CBN model to be more accurate than the CT-CBN model for these datasets.
In real-world applications, the true dependency structure among mutations, i.e. the poset, is not usually known and one has to learn it from observed data. It has been shown that the ML poset is the largest poset that is compatible with all observed genotypes (Beerenwinkel and Sullivant, 2009 ). However, in practice, real-world datasets are not perfect and observations are subject to noise. Hence, since the ML poset only consists of relations that are compatible with all observations, the ML poset will be very sparse for most real-world datasets. The problem of noisy genotypes was addressed in others (2007, 2011) and Beerenwinkel and Sullivant (2009) . In this paper, we follow the approach outlined in Beerenwinkel and Sullivant (2009) . Let P be the maximal poset which consists of all relations which are violated by at most a fraction of all genotypes. The rate parameters λ of the poset P are estimated Fig. 4 . The ML posets learned from the datasets explained in Table 7 of supplementary material available at Biostatistics online. The poset (a) is the ML estimate obtained from both datasets ZDV-fl or ZDV-all. The poset (b)-(d) were learned from the datasets ZDV+ * -all, ZDV+3TC-fl, and ZDV+3TC-all, respectively. These posets explain from 78% to 95% of the input datasets (Table 7 of supplementary material available at Biostatistics online).
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only by using the compatible genotypes. The incompatible genotypes are assumed to be generated with uniform probability q = 1/(2 n − |J (P )|). Then, the probability that a random vector T , defined in (2.1), is compatible with the extended model P is defined as
where the parameter α denotes the fraction of genotypes compatible with the poset P . In Figure 3 , the CT-CBN and OT-CBN estimates for different values of α are compared for the dataset ZDV+3TC-all. For all values of α, the likelihood of the OT-CBN model is larger than the likelihood of the CT-CBN model. The ML poset of the OT-CBN model explains 82% of the observations (Table 7 of 
The p-values are computed from Wilcoxon signed ranked tests of the RMSE of the OT-CBN model versus the CT-CBN model, based on ten-fold cross-validation.
Biostatistics online), this result might be due to the fact that this dataset has the smallest number of observations and hence least statistical power. All ML posets learned from the different datasets consist of two main components (Figure 4 ). The first component consists of the mutations 41L, 210W, and 215Y and the second one consists of the mutations 67N, 70R, and 219Q. This is in agreement with previous studies where two distinct evolutionary routes, called the 215-41 pathway and the 70-219 pathway, were suggested for the development of resistance to HIV under ZDV (Hanna and others, 2000; Beerenwinkel and others, 2005a) . In addition to comparing the likelihoods of two models on the HIV datasets, we also compared the accuracy of sampling time estimation for a given genotype for both models. For real-world datasets, the true rate parameters λ are not known and it is not possible to assess directly the accuracy of the estimated rate parameters. However, we can compare two models by comparing the observed sampling times and the estimated sampling times. The estimation of sampling times depends on the rate parameters and the poset. We can compute the ML estimates of the rate parameters and the poset using the training data of each cross-validation fold. Then, the sampling time for a given genotype is estimated by the expected sampling time E(T s | g, P, λ). In order to compute this expectation, we apply Bayes rule to obtain the posterior distribution of the sampling time,
where the probability P(g | T s = t s , P, λ) is computed by Theorem 2.3 (alternatively denoted by Prob{(T, t s ) Q g } in the theorem) and P(T s = t s | P, λ) is a prior distribution for sampling times. In the cross-validation setting, we approximated the prior distribution by a non-parametric kernel density estimation of training data of each cross-validation fold. Table 1 . For all the HIV datasets, RMSE of the estimated sampling times of the OT-CBN model are significantly smaller than those of the CT-CBN model.
CONCLUSIONS
Timed CBNs have been used to analyze the timeline for the accumulation of mutations under partial temporal orders among mutations. In these models, mutations are assumed to happen after exponentially distributed waiting times. The waiting process for a mutation starts after all its predecessor mutations have already occurred. In previous work, Beerenwinkel and Sullivant (2009) assumed that the sampling time for a given genotype is an unknown exponentially distributed random variable and is independent of the mutational process. Here, in the OT-CBN model, the sampling times are observed and no assumptions on the distribution of the sampling times and its dependency on the mutational process have been made. We developed an EM algorithm for estimation of the evolutionary rates for a given poset based on observed genotypes and corresponding sampling times. We compared the OT-CBN to the CT-CBN model on simulated data as well as real-world data from multiple genotypic HIV drug resistance datasets. In the simulation study, we investigated different sampling time distributions. The OT-CBN model is accurate in recovering true parameters for different distributions of sampling times while the CT-CBN was unable to recover true parameters for distributions that are non-exponential or dependent on the mutational process. For the HIV datasets, the OT-CBN was better than the CT-CBN model in terms of likelihood and sampling time estimation. We conclude that the superiority of the OT-CBN model is the result of less restrictive assumptions of the model as well as taking into account the individual sampling time points for parameter estimation.
We provide an analytical expression for the expected sampling time of a genotype, E(T s | g). This quantity is closely related to the genetic progression score (GPS), defined as the expected waiting time of the genotype, E(max e∈g T e ) (Rahnenführer and others, 2005) . The GPS was previously computed from simulations for a large number of samples obtained from mixture models of timed oncogenetic trees, and it was shown to be a medically relevant prognostic factor for glioblastoma and prostate cancer (Rahnenführer and others, 2005) . Like the GPS, we expect the expected sampling time of the genotype to be an informative predictor of HIV treatment outcome. Since the observation time is a result of treatment failure, it may even be a better predictor of treatment success. Another interesting quantity, computed in this paper in Theorem 2.3, is the probability of observing a genotype at a certain sampling time t s , P(g | T s = t s , P, λ). The probabilities of different genotypes over time (see Example 2.4 and Figure 2 ) are of particular interest for clinicians. This additional information enables clinicians to get more insights about the underlying genotypic information of a patient without performing an actual genotypic resistance testing, which can be helpful in HIV therapy selection particularly in resource-limited countries where genotypic resistance testing may not be available (Prosperi and others, 2010; Revell and others, 2013) .
The OT-CBN model has a number of limitations. Firstly, the use of cross-sectional data for the estimation of the evolutionary rates relies on the assumption of independent observations. The estimation of the rates can be improved by using longitudinal genotypic data where each patient might have more than one genotype at different time points. Further research is required to develop a new CBN model based on longitudinal data (see Beerenwinkel and Drton, 2007) . Secondly, in the HIV application, we found that sampling times cannot be explained solely by the patient's genotype. In other words, we found that the observed sampling times for each genotype are highly variable. This suggests other relevant information of patients such as demographic variables and clinical outcomes have to be taken into account to explain this variability. Further research is needed to fit the CBN model not only based on the observed genotypes and sampling times but also based on other covariates specific to a given patient. This means the evolutionary rates and possibly even the network structure of the CBN model would become patient-specific. Hence, the extended CBN model would be able to describe the dynamics and dependencies of accumulating mutations for each individual patient. This extension could be particularly useful for therapy selection of HIV or in the case of cancer patients where treatment choices are highly personalized. Finally, the OT-CBN model does not work when some of the sampling times are missing. However, there are several ways to overcome this issue. One way is to perform imputation and replace the missing sampling times with sampling times of similar genotypes. A more sophisticated method would be to introduce a more general likelihood function for this case, i.e. (g,t s )∈O Pr{(T, t s ) Q g } g∈M Pr{T Q g } where O is the set of observed genotype-sampling time pairs and M is the set of genotypes for which the corresponding sampling times are missing. The first product is the observed likelihood of the OT-CBN model and the second 724 H. MONTAZERI AND OTHERS one is the observed likelihood of the CT-CBN model. Hence, a combined CT-CBN and OT-CBN approach is possible to overcome missing sampling time issues.
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